Global private equity and venture capital news and research

Amplimmune Series A investor Interwest exits in potential $500m AstraZeneca deal

27 Aug 2013

Interwest Partners-backed US cancer immunology business Amplimmune has been bought by global biopharmaceutical company AstraZeneca in a deal which could reach $500m.

Sorry, to get access to this you need to subscribe for free.

In order to view more content, sign-up to our free daily newsletter.

If you would like to read the premium stories, have complete access to our breaking news and Limited Partner magazine you need to become a Premium Subscriber.

Subscribe to AltAssets today

Login to AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016